Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the activity of 2 oral doses of AB1010 in subjects
suffering from active RA who have shown an inadequate response to one DMARD including MTX or
anti-TNF, after 3 months (12 weeks) of treatment.
The safety and efficacy will be evaluated on:
Rate of patients achieving ACR 20, 50, 70 and 90 DAS (disease activity score) after 3 months
treatment ACRn after 3 months treatment Therapeutic maintenance of AB1010 at 3 months Quality
of Life assessed by SF12 Health Assessment Questionnaire (HAQ) Clinical and biological safety
Pharmacokinetic profile of AB1010